Zanidatamab for injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- BeiGene (Suzhou) Biotechnology Co., Ltd.
- Medicine type
- Biologic
- Therapeutic area
- Oncology
- Indications recorded in the public source
- For previously systemically treated, HER2-high (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer.
- Indication source and scope
- Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- Prescribing-information limitations
- Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Commercial insurance list only; not included in basic insurance
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- The commercial-insurance formulary is not funded by basic medical insurance; coverage depends on the individual commercial insurance contract.
- Insurance verification notes
- Exact match in the commercial insurance list; the basic insurance notice excludes payment.
Sources
- https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=da298734646c4a4ca1b5ca612ee23fb1.pdf
- https://www.nhsa.gov.cn/attach/Ypsnsp2025/YPSW202500365/YPSW202500365.pdf
Open the interactive record, public price references and discussions